Bruker expects full-year earnings in the range of $2.67 to $2.72 per share, with revenue in the range of $3.47 billion to $3.54 billion. Bruker shares have fallen 12% since the beginning of the year.

Barclays analyst Luke Sergott lowered the firm’s price target on Bruker to $65 from $69 and keeps an Overweight rating on the shares. The firm ...

In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Bruker (BRKR – Research Report). The ...

Bruker Corporation today announced the launch of the VERTEX NEO Platform today with its first product, the VERTEX NEO R. This ...

Bruker Corporation (NASDAQ:BRKR) is one of the leading providers of scientific instruments and analytical and diagnostic solutions globally. Its recent acquisitions enhanced its capabilities in ...

Please use one of the following formats to cite this article in your essay, paper or report: APA Bruker Optics. (2025, January 29). Bruker launches infrared imaging microscope for pharma and life ...

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe ...

Bruker’s payout ratio is presently 9.62%. Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic ...

Scientific instrument company Bruker (NASDAQ:BRKR). reported Q4 CY2024 results , with sales up 14.6% year on year to $979.6 ...

Bruker (BRKR) came out with quarterly earnings of $0.76 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.70 per share a year ago. These figures are ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to the ...